Tempus Shares Plummet 3.85% Amid 44.5% Volume Drop Ranks 143rd in U.S. Liquidity

On October 9, 2025, , marking its weakest daily performance in recent sessions. , . equities by liquidity. This volatility suggests renewed investor caution following mixed signals from regulatory developments and market positioning dynamics.

The decline aligns with broader market shifts toward risk-off positioning, though Tempus' underperformance appears exacerbated by specific factors. Recent filings indicated delayed regulatory approvals for its AI-driven clinical trial platform, creating uncertainty around near-term revenue catalysts. Additionally, , reflecting diverging views on the firm's execution risks.

For backtesting purposes, modeling a "top-500-by-volume" strategy requires clarifying key parameters. The universe definition must specify whether to use S&P 500 constituents or dynamically select daily top-volume stocks from the broader U.S. market. Weighting methodologies (equal, volume-weighted, or cap-weighted) and rebalancing frequencies also need confirmation. Output requirements include defining desired metrics (CAGR, volatility, max drawdown) and establishing benchmark comparisons, such as against SPY. Implementation constraints necessitate either testing on a representative index or outlining data-gathering workflows for a more comprehensive analysis.